Form 4: Athira Pharma Director Kelly A. Romano Increases Stake in Company

Director Kelly A. Romano recently purchased additional shares of Athira Pharma, Inc. common stock, increasing their holdings.

Summary

• On June 21, 2024, Kelly A. Romano, a director of Athira Pharma, Inc., purchased 15,000 shares of common stock at a weighted average price of $2.2581 per share.
• These shares were bought in multiple transactions with prices ranging from $2.20 to $2.32.
• Following this transaction, Romano directly owned 53,315 shares.
• On June 24, 2024, Romano purchased an additional 27,400 shares at a weighted average price of $2.4153 per share.
• These shares were bought in multiple transactions with prices ranging from $2.39 to $2.43.
• Following this second transaction, Romano directly owned 80,715 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director increasing their stake can be seen as a positive sign, but it's a single transaction and doesn't provide a comprehensive view of the company's health.

Positives

• A director's increased investment in the company may signal confidence in Athira Pharma's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. Investors often monitor such filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive signal.

Key Dates